Daxor Corp Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
2analysts covering
FY EPS (est.)
-$0.21next fiscal year
Monitoring Framework
Key Performance Indicators
Operating Division Revenue Growth Annually4,500.0%Target: Sustained double-digit growth driven by next-generation portable analyzer placements
Net Asset Value (NAV) per Share Quarterly9.1Target: Maintain premium valuation relative to underlying assets as operating business scales
Operating Division Net Loss Annually-268.6KTarget: Achieve operating break-even
Watch Items
- Transition of regulatory reporting framework from the Investment Company Act of 1940 to the Securities Exchange Act of 1934Trigger: Completion of SEC review and formal order of deregistration under Section 8(f)Action: Monitor SEC filings for the formal transition order, expected to simplify financial disclosures and provide standardized GAAP metrics
- Commercial rollout of the next-generation rapid, compact, and portable Blood Volume AnalyzerTrigger: Initial commercial placements and expansion of the sales team using the $9 million capital raised in January 2026Action: Track quarterly press releases and corporate updates regarding new hospital adoptions and system placements
Research as of 19 Jun 2026